Announcements Trials
Browse Landscape

Phase

Phase NA 3

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3CNS 3Tumor-Agnostic 1Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Brain Neoplasms 3

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Remifentanil × CNS × Clear all
NCT01269918 2016-12-20

RemivsDex

The Cleveland Clinic

Phase NA Completed
142 enrolled 19 charts
CNS

Brain Neoplasms

NCT01545297 2016-07-07

Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery

University Health Network, Toronto

Phase NA Completed
50 enrolled
CNS

Brain Neoplasms

NCT01489137 2012-08-17

The EC90 of Remifentanil Blunting Hemodynamic Changes to Head Fixation

Seoul National University Hospital

Phase NA Completed
50 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡